Bradmer Pharmaceuticals Inc. (TSX: BMR) has closed its private placement under which it has issued 8,369,947 common shares at a price of $0.095 per share which resulted in gross proceeds of $795,000.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
The company will mainly use their proceeds for working capital and general corporate purposes. Completion of the financing is subject to the final approval of the Toronto Stock Exchange.
Bradmer Pharmaceuticals, Inc. is dedicated to the development and commercialization of new and innovative cancer therapies. The Company’s first product candidate, Neuradiab, invented by world-class scientists at Duke University, represents a significant advance in the treatment of certain brain cancers.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
